Clinical trial NCT06826937: Short-Term Recall and Reprocess Therapy for Post Traumatic Stress Disorder (PTSD)
Official title: Short Term Recall and Reprocess Therapy for PTSD
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: PTSD
Post Traumatic Stress Disorder
Keywords: Prolonged Exposure
Massed Therapy
PTSD
Lead sponsor: Ben-Gurion University of the Negev
Sponsor class: OTHER
Collaborators: name: Soroka University Medical Center
name: Soroka Hospital,Beer Sheva,Israel
First posted: 2025-02-14
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: People will be assigned to intervention or waiting list groups. The waiting list will be crossed over 3 months into the study (after the 90 follow-up point)
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if a short-term behavioral intervention, based on imaginal and in-vivo exposure and psychodynamic reprocessing, works on alleviating Post-Traumatic Stress Disorder (PTSD) symptoms in adults. The trial will also learn about patterns of recovery and relapse by following the patients for up to five years. The main questions it aims to answer are:

Does the reconsolidation-based short-term intervention help alleviate PTSD symptoms? How is it affecting other mental health issues (such as depression, sleep problems, and general functioning)? What is the long-term effect of the intervention? Researchers will compare this behavioral intervention to a waiting list, for up to three months. People on the waiting list will then be able to cross over to the treatment arm as well.

Participants will:

Be screened by a clinical psychologist Take the week-long intensive behavioral intervention (psychotherapy) Followed at the end of treatment (day 7), at 30 and 90 days, and every 6 months, up to five years.

Wearable devices will be used during the week before treatment, during treatment, and up to 30 days following the end of treatment.


Eligibility criteria: Inclusion Criteria:

* • Diagnosis of PTSD with a score of 25 or higher (i.e. severe PTSD) on the Clinician- Administered PTSD Scale (CAPS-5) at screening.

  * Subjects on FDA-approved antidepressants, trazodone, atypical neuroleptic, prazosin, or clonidine may enter the study if they have been on a stable treatment, as determined by the study clinician, for at least 4 weeks prior to randomization. Following randomization, small changes to doses may be allowable at the PI's discretion.
  * Able to provide written informed consent.
  * Able to read and write English/Hebrew.

Exclusion Criteria:

* • Patients with a diagnostic history of bipolar disorder, borderline personality disorder, obsessive-compulsive disorder, schizophrenia or schizoaffective disorder or currently exhibiting psychotic features as determined by the clinical interview; dementia or suspicion thereof, are excluded. Other DSM Axis I disorders are permitted as long as they are not considered primary disorders.

  * Patients with a history of antidepressant-induced hypomania or mania as determined by open-ended psychiatric interview.
  * Current, ongoing serious suicidal risk as assessed by evaluating.
  * Moderate severity or greater Substance Use Disorder (excepting Alcohol Use Disorder) during the 3 months prior to randomization, as determined by the SCID.
  * History of traumatic brain injury (TBI) with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days may be considered if the trauma occurred more than 1 year ago, and no more than minimal symptoms have persisted over the past year.
  * Any significant history of neurological illness or heart disease.
  * Any signs of major medical or neurological illness on examination or as a result of ECG screening or laboratory studies.
  * Any history indicating learning disability or mental retardation.

Primary outcomes:
measure: Changes in PTSD symptoms (PCL-5)
timeFrame: At screening, at the end of treatment (i.e., 7 days following the initiation of the treatment), at 30 days, at 90 days and up to 5 years follow-up (bi-annualy, i.e., every six months))
Secondary outcomes:
measure: Improved sleep
timeFrame: 6 weeks total. One week before the beginning of the treatment, during treatment and up to 30 days follow-up.
measure: Depressive symptoms
timeFrame: At screening, at the end of treatment (i.e., 7 days following the initiation of the treatment), at 30 days, at 90 days and up to 5 years follow-up (bi-annualy, i.e., every six months))
Other outcomes:
Locations:
city: Beer-Sheva
country: Israel
facility: Ben Gurion University of the Negev
Study officials:
References: